Oct 21 (Reuters) – Fortress Biotech Inc: * FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE FIRST PATIENTS DOSED IN CRYSTALYS THERAPEUTICS’ GLOBAL PHASE 3 TRIALS OF DOTINURAD FOR THE TREATMENT OF GOUT Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Medha Singh Feb 5 (Reuters) - Shares of U.S. software and data services companies…
By Sam Tobin LONDON, Feb 5 (Reuters) - British singer Elton John's husband, David Furnish,…
Feb 5 (Reuters) - Spotify said on Thursday it will begin selling physical books on…
Feb 5 (Reuters) - Spotify said on Thursday it will begin selling physical books on…
Feb 5 (Reuters) - Spotify said on Thursday it would begin selling physical books on…
(Updates for market open, changes dateline from BEIJING/PARIS to CHICAGO) By Heather Schlitz CHICAGO, Feb…